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Background:Mitochondrial accumulation of amyloid  (A) promotes organelle dysfunction and Alzheimer disease (AD)
neuropathology.
Results: IDE-Met1 localizes in mitochondria, is present in brain, and is regulated by the master regulator of mitochondrial
biogenesis.
Conclusion:Mitochondrial biogenesis controls mitochondrial A levels.
Significance:This study identifies amolecularmechanism that linksmitochondrial biogenesis withA degradation, suggesting
that deregulation of this pathway could induce A-mediated mitochondrial dysfunction.
Studies of post-mortem brains from Alzheimer disease
patients suggest that oxidative damage induced by mitochon-
drial amyloid  (mitA) accumulation is associated with mito-
chondrial dysfunction. However, the regulation of mitA
metabolism is unknown.Oneof the proteases involved inmitA
catabolism is the long insulin-degrading enzyme (IDE) isoform
(IDE-Met1). However, the mechanisms of its expression are
unknown, and its presence in brain is uncertain. We detected
IDE-Met1 in brain and showed that its expression is regulated by
the mitochondrial biogenesis pathway (PGC-1/NRF-1). A
strong positive correlation between PGC-1 or NRF-1 and long
IDE isoform transcripts was found in non-demented brains.
This correlation was weaker in Alzheimer disease. In vitro inhi-
bition of IDE increasedmitA and impairedmitochondrial res-
piration. These changes were restored by inhibition of -secre-
tase or promotion of mitochondrial biogenesis. Our results
suggest that IDE-Met1 links the mitochondrial biogenesis path-
way withmitA levels and organelle functionality.
Mitochondrial dysfunction is believed to play an important
role in human diseases, including diabetes mellitus type 2, can-
cer, and neurodegenerative disorders such as Alzheimer (AD)2
and Parkinson diseases (1, 2). The proteolytic system in mito-
chondria is crucial for themaintenance of protein turnover and
integrity of the organelle. Several proteases have been identified
inmitochondrial subcompartments amongwhich presequence
protease and insulin-degrading enzyme (IDE) through their
capacity of degrading amyloid  (A) peptide may be impli-
cated in AD neuropathology. Although the amyloid plaques
characteristic of AD consist of extracellular A aggregates,
accumulating data suggest that A peptide may exert toxicity
within the cell (3).
Interestingly, humanPreP (hPreP) is an organellar functional
analog of human IDE (hIDE). Both proteins belong to the pitri-
lysin M16 family of proteases containing an inverted Zn2-
binding motif. In contrast to hPreP, which was described only
in mitochondria, hIDE is ubiquitous both at tissue and cellular
levels (4, 5) and is considered a multifunctional protein
involved in proteolysis-dependent and -independent cellular
processes (for a review, see Ref. 6).
hPreP and hIDE are encoded by single genes PITRM1 and
IDE, respectively, on chromosome 10. In silico and in vitro stud-
ies demonstrated that PreP is a matrix mitochondrial protease
(7). The 5 hIDE promoter region is CpG-rich with multiple
transcription start sites with transcripts comprising one or two
possible translation start sites (5). Depending on which starting
AUG codon is translated, IDE proteins starting at Met1 and/or
Met42 may be produced. The N terminus of the long variant
(IDE-Met1) has a sequence that predicts mitochondrial impor-
tation (8). Mitochondrial localization of IDE was confirmed in
vitro (8, 9); however, its relevance in vivo is unknown. By using
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in vitro degradation assays with synthetic peptides as sub-
strates, significantly lower activity of hPreP isolated from tem-
poral lobes of the brains of AD cases and of transgenic mice as
models of AD was recently reported (10), suggesting a crucial
role of PreP in the clearance of mitochondrial A (mitA) (11).
In regard to expression and activity of cytosolic IDE in AD
brains, there are still controversies with reports showing decre-
ments (12–15), increments (16, 17), or no changes (18, 19). It
has been proposed that part of the loss of IDE and PreP activi-
ties in AD brain may be due to oxidative damage to which both
proteases are highly sensitive (7, 20). Despite IDE involvement
in extracellular A peptide clearance, little is known about the
regulation of IDE-Met1 expression and its relevance in mitA
metabolism. The molecular mechanisms that govern the pro-
moter activity of hPreP and hIDE-Met1 are still unknown.
However, recent reports showed that the hIDE promoter may
be a direct target of PPAR (21), HES-1/Hey-1 (key down-
stream targets of Notch signaling) (15), and NRF-1 (22). NRF-1
interacts with peroxisome proliferator-activated receptor 
coactivator 1 (PGC-1) family proteins (23) to inducemitochon-
drial biogenesis. Upon appreciation that mitochondrial IDE
content can be influenced by these coactivators and that the
reported impaired mitochondrial biogenesis contributes to
mitochondrial dysfunction in AD, we hypothesized that IDE-
Met1 impacts mitA homeostasis through mitochondrion-re-
lated cell signalingmechanisms. Given thatmanymitochondri-
on-related events are regulated by PGC-1 and NRF-1 (24), we
assessed whether pyrroloquinoline quinone (PQQ), a mito-
chondrial biogenesis stimulator (25), enhances IDE-Met1
expression and reverts mitochondrial dysfunction in a cellular
model of A accumulation. Taken together, our results identify
in cell culture experiments and in human brain an unantici-
pated link between master genes of mitochondrial biogenesis
and IDE-Met1 up-regulation thatmay open avenues to enhance
mitA clearance and thereby halt disease progression.
EXPERIMENTAL PROCEDURES
In Silico Analysis of hIDE Gene—The genomic sequence of
the 5021 base pairs (bp) corresponding to the promoter of the
human IDE gene (5039/18 upstream of the first translation
start site, ATG) was obtained from GenBankTM (accession
number NG_013012). Different programs were run to predict
transcription factor consensus binding sites: TESS (Transcrip-
tion Element Search System), TF Search software, Genomatix,
Regulatory Sequence Analysis Tool, Signalscan, Jaspar, Trans-
fac, and MitoProt-II v1.101.
RNA Secondary Structure and Stability Predictions—The
first 185 nucleotides (from 39 to 146) and 119 nucleotides
(from 27 to 146) of IDEmRNA (considering as 1 the adenine of
the first translation start site)were analyzed. Theminimum free
energy structure and the suboptimal folding structures were
calculated with Zuker and Turner Mfold software, version 3.2.
The single strand probability was estimated from the Mfold
results by normalization of the ss-count using a specific Perl
script. To compare the stability of the 5 fraction of the long and
short IDE transcripts, the first 100 nucleotides of both RNA
species were used. The free energy was calculated with Mfold
and used to calculate the stability per nucleotide for both
transcripts.
Transcription Start Site (TSS) Identification—TSS was
obtained using a rapid amplification of cDNA 5-end kit, sec-
ond generation (Roche Applied Science). Final PCR products
were analyzed in 8.4% acrylamide/bisacrylamide Tris borate-
EDTA gels. The purified DNA was subcloned into TOPO TA
cloning vector (Invitrogen), and 20 clones were sequenced for
each experiment. The sequences of primers are listed in Table 1.
Deletions and Mutations on IDE Promoter Constructs—De-
letion constructs of the IDE gene promoter (1209/19,
575/19, 118/19, and 82/19) were derived by PCR
from bp 5039/18 of the 5 upstream region of human IDE
gene (kindly provided by Dr. W. Farris, Pittsburgh University).
In addition, two different constructs (118/59 and 19/59)
including 59 bp downstream of the first TSS were generated
from genomic DNA by PCR. Forward and reverse primers and
restriction sites are listed in Table 1. PCR-amplified fragments
were inserted upstreamof the luciferase (LUC) reporter gene in
the pGL3-Basic vector (Promega). The correct sequence and
orientation were confirmed by sequencing (Macrogen, Korea).
Mutations in the IDE promoter were generated by PCR using
TABLE 1
Sequences of oligonucleotides used in this study
The oligonucleotide sequences used for PCR, site-directed mutagenesis, methylation status of hIDE core promoter, and gel retardation experiments (28) are given.
Method Primer Sequence (5–3) (restriction site)
PCRa OUTER GCAATATTTGGAGGATCCGACAAT
R147 TCTCTTGATGGCTGGATTATTCAT
R59 ACTGAGCGGAAGGTGCTGGGCAGT
R98 TTGGAAAACCCATTCTTGAGG
F (1209) GTATGGTACCCTCTGCATTGGGACTG (KpnI)
F (575) GTATGGTACCCACGCCGCACTCGA (KpnI)
F (118) GTATGGTACCTCTCCGCAGCTCC (KpnI)
F (82) GTATGGTACCGCTAGAGCATGCGC (KpnI)
F (19) GTATCTCGAGCCGGCGACTGCGCTGG (XhoI)
R (19) GACTAAGCTTGATCACCGCAAACGCT (HindIII)
R (59) GACTAAGCTTCTGCGCACTGCGCA (HindIII)
Site-directed mutagenesisb NRF-1 mut1 GCCGCGGCTAGAAAATGCGCAGTGCGCAGGGCCGGCTCGAAGCGC
NRF-1 mut2 GCCGCGGCTAGAGCATGAACAGTGCGCAGGGCCGGCTCGAAGCGC
Methylation status of hIDE core promoter CpG-F GGAAAGTCTGGGTGCTGGCTC
CpG-R TTAAGTGCTGAATCACCACTTTGCAAC
EMSA IDEWT CCGCGGCTAGAGCATGCGCAGTGCGCAGGG
IDE MUT CCGCGGCTAGAAAATGAACAGTGCGCAGGG
a Restriction site sequences are shown in italics and underlined.
b Mutated bases are shown in bold and underlined.
Long Isoform of IDEModulatesMitochondrial Functionality
MAY 3, 2013•VOLUME 288•NUMBER 18 JOURNAL OF BIOLOGICAL CHEMISTRY 12921
 by guest on July 9, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
sense and antisense primers (Table 1). All of the constructs
were verified by DNA sequencing (Macrogen).
Luciferase Reporter Assay—48 h after transfection, cell
lysates were obtained, and luciferase activities were measured
using the Dual-Luciferase assay kit (Promega) according to the
supplier’s instructions. Results are expressed as relative lucifer-
ase activity normalized (100) to the construct that showed the
highest activity. The light intensity was measured using a lumi-
nometer (Tecan Genius).
Plasmid DNA Constructs—The human NRF-1 expression
constructs wild type (WT) and dominant negative (DN)
(pcDNA3-FLAG-WT-NRF-1 and pcDNA3-FLAG-DN-NRF-1)
were provided by Dr. Kimitoshi Kohno (University of Occupa-
tional and Environmental Health, Japan) (26). Human myc-
PGC1 plasmid was obtained fromAddgene.
Cell Cultures and Treatments—U87 (human glioma cells),
HeLa (human epithelial cells), SK-N-SH (human neuroblas-
toma cells), were cultured following conditions described by
ATCC. OLN-93 (rat oligodendroglial cells; kindly provided by
Dr. Richter-Landsberg, University of Oldenburg, Germany)
were cultured as previously reported (60). Human embryonic
kidney (HEK293) cells stably transfected with human Swedish
mutant APP (HEKSw; a generous gift fromDr. Sisodia, Univer-
sity of Chicago) were cultured in Dulbecco’s modified essential
medium (DMEM), high glucose supplemented with 10% fetal
bovine serum and G418. The impact of intracellular A levels
was determined inHEKSw cells treated or not with 1MDAPT
(Calbiochem), a -secretase inhibitor, for 18 h. Mitochondrial
biogenesis was stimulated by PQQ (provided as a gift fromMit-
subishi Gas and Chemical, Japan) treatment (30 M for 24 h)
(25).
Transient Transfections and Cellular Sensibility Assay—For
LUC reporter assay experiments, cells were plated at 4 
104cells/well in a 24-well plate 18 h prior to transient transfec-
tion. Each well was transfected with 420 ng of IDE promoter
construct and 80 ng of pCMV Renilla vector. For NRF-1 or
PGC-1 expression, cells were plated at 1.5  106 cells/
100-mm dish 16 h prior to transient transfection. In all cases,
transfection was performed with Lipofectamine LTX (Invitro-
gen). HEKSw cells were transfected with 50 nM IDE siRNA or
non-targeting siRNA (Dharmacon) using jetPRIME (Polyplus)
reagent. The silencing effect was analyzed 72 h post-transfec-
tion by RT-qPCR or ELISA. Cellular viability was assessed in
transfected cells through the reduction of 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide by mitochondria.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide was incubated at 0.5 mg/ml for 4 h at 37 °C in darkness,
and the products of reaction were dissolved in DMSO. Absor-
bance was measured at 570 nm, and viability was expressed as
the percentage relative to untransfected cells.
Human Tissues—Frozen samples of hippocampus from late
onset sporadic AD Braak stage V (n  7) and non-demented
age-matched controls (ND; n 4) were kindly provided by the
Harvard Brain Tissue Resource Center (Boston, MA). Clinical
and pathological features of each group were described previ-
ously (15). The methylation status of cytosines in the NRF-1
binding site of IDE core promoter was performed using the
CpGenome DNA modification kit (Chemicon) followed by
PCR amplification with a set of primers (CpG-F and CpG-R)
detailed in Table 1. The PCR products were cloned in pGEM-T
vector (Promega), and 10 colonies of each subject were
sequenced (Macrogen).
Immunoprecipitation of IDE from Rat and Human Brains—
Rat brains were obtained from adult Sprague-Dawley animals
following protocols approved by the Fundación Instituto Leloir
ethics committee. Tissues were homogenized, and IDE was
immunoprecipitated using a set of specific anti-IDE mouse
IgG1 monoclonal antibodies (1C1 and 3A2) developed in our
laboratory as reported previously (17)
“In-gel” Digestion and Mass Spectrometry (MS) Analysis—
Immunoprecipitated IDE separated by SDS-PAGE was pro-
cessed for in-gel digestion and MS analysis as described previ-
ously (27). The precision in analyses was equal or less than an
error of 0.1%. The negative control included digested fragments
from gels corresponding to immunoprecipitations with IgG
unrelated to IDE.
Electrophoretic Mobility Shift Assay—The electrophoretic
mobility shift assay was performed as described (28). Nuclear
extracts were obtained following the rapid protocol for DNA-
binding protein (29). Oligonucleotides (Table 1) were biotiny-
lated at their 5-end and purified by HPLC (Genbiotech). Bind-
ing and competition reactions and blots were performed
following the LightShift chemiluminescent EMSA (Pierce)
protocol.
Chromatin Immunoprecipitation (ChIP) Assay—Cells were
cross-linked, harvested in lysis buffer, and sonicated using a
sonicator (Bioruptor UCD-200, Diagenode). Chromatin was
incubated overnight at 4 °C in a rotation platform with goat
anti-NRF-1 serum (kindly provided byDr. RichardC. Scarpulla,
Northwestern University Medical School, Chicago, IL) or nor-
mal goat serum as a negative control (30). Primers F-118 and
R59 (Table 1) were used to amplify the 177-bp IDE promoter
(from 118 to 59). The cycling conditions were as follows: 5
min at 94 °C followed by 35 cycles of 94 °C for 30 s, 54 °C for 1
min, and 72 °C for 30 s. ThePCRproductswere resolved in 8.4%
acrylamide/bisacrylamide Tris borate-EDTA gels.
RNA Isolation and RT-qPCR—One microgram of total RNA
was reverse transcribed using the IDE-specific primer R98
(sequence detailed in Table 1), oligo(dT) primer, and Super-
Script II reverse transcriptase (Invitrogen) (15). cDNA was
amplified by SYBR Green RT-qPCR with a Mx3005P cycler
(Stratagene). Cycling conditions were as follows: 94 °C for 10
min, 94 °C for 30 s, annealing for 1 min at 58 °C, and 72 °C for
30 s for 40 cycles. Melt curve analysis and agarose gels verified
the formation of a single desired PCR product. The relative
amount of transcripts to hypoxanthine phosphoribosyltrans-
ferase or TATA-binding protein was quantified by the 2CT
method using MxPro software. The relative expression of the
genes in human brain was determined by comparison of Ct
using the following equation: RAD/RNDC (CtxAD CthAD)
(CtxNDC CthNDC) (31).
Mitochondrial Respiration—Mitochondrial oxygen con-
sumptionwas performed in intact cells polarographicallywith a
Clark-type oxygen electrode in a two-channel respirometer for
high resolution respirometry (HansatechOxygraph,Hansatech
Instruments Ltd., Norfolk, UK). Confluent monolayers were
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resuspended in 64 M digitonin for 10 min and centrifuged at
600 g for 5 min. Pellets were resuspended in PBS and used as
samples. Mitochondrial respiratory rates were measured in a
reaction medium as described (32). To achieve a resting respi-
ration state, 2M oligomycin was used as a F0-F1 ATP synthase
inhibitor (state 4o). To evaluate active respiration, the protono-
phore 2 M carbonyl cyanide m-chlorophenylhydrazone was
added to reach uncoupled respiration (state 3u). Results were
expressed as ng-atoms of oxygen/mg of cell protein. Respira-
tory control ratio (RCR) was calculated as the relationship
between state 3u respiration and state 4o respiration (33).
Synchronization of Cells and Measurement of the Mitochon-
drial Mass—Cells were synchronized in G0 phase as described
previously (34), then washed, and cultured in the presence or
absence of PQQ for 48 h. After trypsinization, cells were fixed
with cold 70% ethanol, washed, and stained with 10 mM 10-N-
nonyl acridine orange (35) for 10 min at room temperature in
the dark. After washes with cold PBS, cells were immediately
analyzed by flow cytometry (FACSCalibur) with the software
Cell Quest (BD Biosciences).
Mitochondrial DNAContent—The amount ofmitochondrial
DNA was estimated by qPCR using KAPA SYBR FAST qPCR
MasterMix (Kapa Biosystems). Total DNAwas extracted using
the GFX genomic blood DNA purification kit (GE Healthcare).
PCRs contained 1 ng of DNA and a 0.5 M concentration of
each primer of a subunit of the human electron transport chain
as described previously (36).
Quantification of IDE and A40 Levels—Mitochondria were
isolated by using supramagnetic microbeads (Miltenyi Biotec).
After the application of the cell lysate onto the column, mito-
chondria were retained, and the flow-through was collected
and centrifuged at 100,000 g to further analyze the cytosolic
fraction. Eluted mitochondrial fractions were sonicated in PBS
containing a mixture of protease inhibitors. IDE levels were
quantified by a sandwich ELISA with a set of specific anti-IDE
monoclonal antibodies (3A2 to capture and biotinylated 1C1 to
detect IDE, respectively) as reported previously (17), and A40
levels were quantified using a commercial ELISA kit (Invitro-
gen). Data for each set of duplicate experiments were normal-
ized by the protein content and expressed for IDE as ng/mg or
as percentage as compared with mock-transfected cells
(100%) and for A40 as pg/mg.
Statistical Analysis—All experiments were performed at
least in triplicate, and values are presented asmeans S.E.Data
were analyzed by Student’s t test using GraphPad Prism 3.0
software. Statistical significance was set at p 0.05.
RESULTS
The First AUG of Endogenous hIDE mRNA Is Translated in
Vivo—To characterize transcription start sites, total RNA from
the U87 human cell line was amplified with an IDE-specific
reverse primer anchored in the middle region of exon 1 (bp
36–59 where 1 refers to adenine of the first putative translated
ATG expressed as DNA) (Fig. 1A). PCR products (Fig. 1B,
upper panel) revealed multiple 5 start sites at positions
between 40 and 28 (Fig. 1B, lower panel) included in a CpG
island located at position 53/42 (data not shown) with the
following characteristics: observed/expected ratio, 	0.6; per-
cent C  percent G, 	60.00; length, 	200. The CpG island
predicted contains all TSSs detected. Although rapid amplifi-
cation of cDNA 5-end is not a strictly quantitativemethod, the
abundance of clones obtained suggested that in U87 cells the
most abundant TSS lies within this region. Our results were
concurrent with information in the Database of Transcrip-
tional Start Sites (Release 8.0; based onUCSCGenomeBrowser
hg19, mm9) in which all mRNA 5-ends (from bp 75 to 36)
were localized within exon 1. As shown in Fig. 1C, the 5-end of
the long IDE (L-IDE) mRNA region containing both putative
FIGURE 1. Schematic representation of hIDE promoter region. A, primer positions used for the rapid amplification of cDNA 5-end (5RACE). B, upper panel,
the asterisk indicates the heterogenic composition of the product obtained from the second PCR resolved in an 8.4% Tris borate-EDTA polyacrylamide gel. On
the left aremarkers in bp. Lower panel, arrows indicate different transcription start sites identified in the40/28 region of the hIDE promoter. The first putative
translation start site (DNA) isunderlined.C, predictionof RNA secondary structure (minimum free energy) of L-hIDE showingbothputative translation start sites
(asterisks). Thebases are coloredaccording to the calculatedprobability tobea single strand: red, probability greater than0.75;orange, probability greater than
0.5 and lower than 0.75; and black, probability lower than 0.5.
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translation start sites that may generate IDE-Met1 and/or IDE-
Met42 is predicted to be highly structured. However, both puta-
tive sites have a high probability to be single strand regions and
are plausibly recognized by RNA polymerase. Next, we com-
pared the stability predicted for the 5-end of L-IDEmRNAand
short IDE (may produce only IDE-Met42) and showed that the
estimated stability for L-IDE mRNA is 10 kcal higher than that
predicted for the short IDE (34.9 versus24.0 kcal/mol). To
determine whether the long isoform of IDE (IDE-Met1) is tran-
scribed in the brain, we immunoprecipitated IDE from human
and rat cortical homogenates, and after in-gel digestion with
endo-Lys-C, proteolytic fragments were characterized by
MALDI-TOFMS (Fig. 2A, lower panel). These peptides were in
full agreement with the expected major sites of human IDE-
Met1, reinforcing the concept that IDE-Met1 is transcribed and
translated in the human brain. Similar results were obtained
with rat brain homogenates (Fig. 2B).
Transcriptional Regulation of L-IDE mRNA Is Mediated by
the Mitochondrial Biogenesis Pathway—To define the bound-
aries of the minimal hIDE promoter, we prepared a series of
truncated constructs (Fig. 3A) and tested them in different cell
lines by transfection using the LUC reporter system. IDE
118/59 showed the strongest transcriptional activity in differ-
ent human and rat cell lines (Fig. 3, B–E). As compared with
promoter activity of IDE118/59, a 3 deletion of 118 bp (IDE
118/59) or a 5deletion of 78 bp (IDE 19/59) drastically
reduced LUC activity to 
20 and 
1%, respectively, in all cell
lines analyzed, indicating that this DNA sequence contains the
minimal region with hIDE promoter activity. Moreover, this
region covers all the IDE TSSs reported so far, which may
explain the highest levels of LUC expression obtained with this
DNA fragment. By using prediction programs for transcription
factor binding sites and multiple sequence alignment, we con-
firmed that the NRF-1 binding site is the most frequently iden-
tified and highly conserved among different species as reported
recently (22). We analyzed the relevance of the NRF-1 putative
binding site to IDE core promoter activity by introducing dis-
rupting point mutations in the NRF-1 site and testing the
mutant constructs in theU87 cell line using a LUC assay.Muta-
tions of the NRF-1 site demonstrated that it played a positive
regulatory role in human IDE transcription activity. The puta-
tive site of NRF-1 in the human IDE core promoter is a 12-base
sequence, 5-AGAGCATGCGCA-3, with one cytosine in the
context of CpG plausibly methylated.3 When the hemicores
AGAGC and GCGCA were replaced by AGAAA and GAACA,
a drastic, almost complete loss of promoter activity was
observed (Fig. 3F), consistent with the finding that homodi-
mericNRF-1 binding toDNA is required for full transcriptional
activity as reported (24). Similar results were obtainedwhen the
construct IDE118/59was in vitromethylated (Fig. 3G). These
results point to a crucial role for the NRF-1 DNA motif in IDE
3 L.-C. Li, personal communication.
FIGURE 2. In vivo identification of IDE-Met1 isoform. A and B, upper panels,
schematic representation of the amino acid sequences (1–56) of hIDE (A) and
rat IDE (B) showing two alternative in-frame initiationMet residues, Met1 and
Met42 (bold). The arrowheads indicate the predictive cleavage sites in the N
terminus of IDE-Met1 isoform by endo-Lys-C. Solid lines below depict the
expectedpeptidesobtainedafterdigestion.AandB, lower panels,MALDI-TOF
MS analysis of the peptides (P1, P2, and P3) obtained after endo-Lys-C diges-
tion. Insets, hIDE (H-IDE) and rat IDE (R-IDE) species and expected/calculated
masses of predicted peptides. Cys-CM, carboxymethyl-Cys; A.U., arbitrary
units; Obs., observed; Calc., calculated.
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core promoter activity. To determine whether the NRF-1 bind-
ing site on the IDE promoter was effectively recognized by
endogenous NRF-1 protein, we performed EMSA (Fig. 4A) and
ChIP assays (Fig. 4B).Our results showed the specific binding of
NRF-1 to the hIDE promoter region in vivo as was previously
suggested in a ChIP-on-chip analysis (37). The requirement of
NRF-1 for effective IDE promoter activity was further studied
by co-transfection of FLAG-tagged DN-NRF-1 with the
reporter construct IDE 118/59. As shown in Fig. 4C the IDE
118/59 promoter activity upon expression of FLAG-DN-
NRF-1 was inhibited in a dose-dependent manner (40 and 30%
after 0.1 or 0.2g, respectively, of DN-NRF-1 plasmid transfec-
tion). Then, to analyzed whether NRF-1 regulates transcription
of L-IDE mRNA, which comprises the two possible translation
start sites, we designed primers to quantify the L-IDE mRNA
sequence detected by rapid amplification of cDNA 5-end (Fig.
1A) and measured its levels by RT-qPCR in cells transfected
with DN-NRF-1 or WT-NRF-1. In both cases, the correct
expression of constructs was confirmed by immunoblotting
with anti-FLAG antibody (38) (Fig. 4D). L-IDE mRNA showed
a 15-fold reduction after DN-NRF-1 transfection and an

3-fold increment when WT-NRF-1 was expressed as com-
pared with control (Fig. 4E, left panel). To dismiss that cell
death might have contributed to the striking reduction
observed in DN-NRF-1-transfected cells, we performed a via-
bility assay. Viability greater than 70% was observed in both
experimental conditions with no statistical differences between
mock- and DN-NRF-1-transfected cells (83.37  0.09% versus
78.46 1.680%).
Taking into account that PGC-1 is a mitochondrial regula-
tor that induces NRF-1 overexpression, we assessed whether
PGC-1 is involved in L-IDE expression. In accordance with
our prediction, NRF-1 levels were increased 2-fold and L-IDE
levels were increased 
3-fold in PGC-1 as compared with
mock-transfected cells (Fig. 4E, right panel), showing the posi-
tive activation of PGC-1 on NRF-1 and L-IDE transcription,
respectively. To assess whether the PGC-1/NRF-1 pathway
has a restricted effect on IDE-Met1 or not, we determined the
levels of IDE protein in mitochondria (IDE-Met1) and cytosol
(IDE-Met42) of WT-NRF-1, DN-NRF-1, and PGC-1 tran-
siently transfected cells, respectively. Our results showed a
significant reduction in the percentage of IDE in themitochon-
drial fraction of DN-NRF-1 as compared with mock-trans-
fected cells (100%) (Fig. 4F, left panel), suggesting that NRF-1
FIGURE 3. NRF-1 mediates the transcription of the core promoter of human IDE and is sensitive to methylation. A, schematic representation of the
deletionmutants derived from the bp5039/18 construct and generated by PCR. Bars show themean S.E. of the percentage of LUC activity determined
in U87 (B), SK-N-SH (C), HeLa (D), and OLN-93 (E) cells transfected with each construct, respectively. In each experiment (n 3), the construct that showed the
highest LUC activity represents 100%. All of the constructs showed significant differences as compared with the118/59 hIDE promoter region. *, p 0.01.
F, schematic representation of the NRF-1 mutated sites generated by site-directed mutagenesis from the 118/59 hIDE promoter region. Bars show the
mean S.E. of relative LUC activity determined in U87 cells transfected with each construct, respectively (n 4). *, p 0.01 versusWT construct. G, left panel,
the promoter activity of construct118/59 was measured after treatment without () or with () methyltransferase. Right panel, products of DNA digestion
to test the methylation state for each condition. Error bars represent S.E. au, arbitrary units.
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has a direct impact onmitochondrial IDE levels. By contrast, we
did not detect any significant difference in mitochondrial IDE
protein levels after WT-NRF-1 transient transfection (Fig. 4F,
left panel). These resultsmay be the consequence of at least two
factors: themoderate increment of the target genes both in vivo
(39) and in vitro (40) after the overexpression of NRF-1 as
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reported previously and the extended half-life of IDE (
33 h)
(41) that may mask the slight increments that are a conse-
quence of the 3-fold increase in the L-IDE mRNA. Moreover,
our results suggest thatNRF-1 had no detectable effect on cyto-
solic IDE because neither WT-NRF-1 nor DN-NRF-1 modu-
lated cytosolic IDE protein expression. In addition, in cells
transfected with PGC-1, the levels of IDE in both subcellular
compartments increased as compared with mock-transfected
cells (145.6% 42.05% and 200 69.9%) without a significant
difference between mitochondria and cytosol (p  0.5). Con-
sidering that in addition to NRF-1 overexpression PGC-1 also
greatly increases the transcriptional activity of PPAR (42) and
that PPAR has a direct impact on the IDE 5-UTR upstream of
the minimal promoter (21), our results suggest that PGC-1
up-regulates both IDE isoforms.
A time course analysis of PGC-1, NRF-1, and L-IDE tran-
script levels in HEKSw cells showed that PGC-1 increased its
expression significantly at 30 min after PQQ treatment (Fig.
4G) as compared with mock-transfected cells (p  0.01) and
then decreased from 30 min to 4 h with no significant differ-
ences as compared with mock-transfected cells (p 	 0.05),
whereas the transcripts of NRF-1 and L-IDE showed a signifi-
cant increment after 1 (p 0.05) and 2 h (p 0.01) of exposure,
respectively, suggesting that L-IDE is a target of the mitochon-
drial biogenesis transcriptional pathway. To assess whether
A40 accumulation affects mitochondrial biogenesis in
HEKSw cells, we determined mitochondrial DNA levels in
PQQ-treated cells in the presence or absence of a -secretase
inhibitor (DAPT).Our results showed thatmitochondrial DNA
content increased
57%whenHEKSw cells were preincubated
with DAPT, suggesting that A40 accumulation affects mito-
chondrial biogenesis (data not shown).
To determine whether the PGC-1/NRF-1/L-IDE pathway
is altered in AD brain, we evaluated the methylation status of
seven CpGs in the context of the NRF-1 binding site of the IDE
promoter in hippocampal samples fromND andADbrains and
found that the percentage of methylation was similar (97.1 ver-
sus 98.5%). However, we found that in ND there was a positive
strong correlation between the expression of PGC-1 (r2 
0.83) or NRF-1 (r2  0.94) and L-IDE (Fig. 5, upper panels)
mRNAs. By contrast, in AD brains, the correlation was weaker
with values of r2  0.012 and r2  0.32 for PGC-1 or NRF-1
and L-IDE, respectively (Fig. 5, lower panels). These results
agree with the recent reported lower levels of PGC-1 and
NRF-1 in AD as compared with ND (36). However, because of
the low number of brains analyzed when the test of comparison
of correlation coefficients was applied, the values of the statistic
were 0.894 and 0.857 for PGC-1/L-IDE and NRF-1/L-IDE,
respectively, suggesting that there is not sufficient evidence to
affirm that both populations (AD and ND) have different cor-
relation coefficients for each of the variables analyzed.
The Enhancement of L-IDE Expression Reverts theMitochon-
drial DysfunctionMediated by mitAAccumulation—To eval-
uate the impact of IDE-Met1 expression onmitAhomeostasis,
mitochondria were isolated from HEKSw (Fig. 6A) transfected
with control or IDE siRNA. After down-regulation of IDE (Fig.
6B),mitAwas increased (6.4 2.4 versus 17.12 2.62 pg/mg)
(Fig. 6C), suggesting thatmitA is regulated by IDE. The anal-
ysis of oxygen consumption by isolated mitochondria is the
classical approach to characterize mitochondrial function. The
HEKSw cells showed a decrement of 
22% in the RCR value
compared with HEK cells (1.73 0.04 versus 2.22 0.02; p
0.05), reinforcing the concept that intracellular accumulation
FIGURE 4. Transcriptional regulation of L-IDEmRNA is mediated by themitochondrial biogenesis pathway. A, the labeled oligonucleotides containing
the canonical NRF-1 binding siteswere used as probes and incubatedwith nuclear extracts fromHeLa cells alone (lane 2) or in competitionwith 50- or 100-fold
excess amounts of unlabeledprobe (lanes 3 and 4, respectively). SpecificDNA-protein complexes formedare indicated (arrow). Themutant (mut.) probes failed
to form specific DNA-protein complexes (lane 6). To identify the DNA-binding proteins in an antibody (Ab) disruption assay, polyclonal antibodies specific to
NRF-1 or normal rabbit control IgGwere added to the binding reactions and incubated for 20min at room temperature before probeswere added (lanes 9 and
10). B, the association of the transcription factor and the NRF-1 motif on the hIDE promoter was examined in intact HeLa cells by PCR amplification of the
sequence between118 and 59 after chromatin immunoprecipitationwith specific antiserum (anti-NRF-1). As a positive control, the NRF-1 binding region of
the hIDE promoter was PCR-amplified from genomic DNA. The fragment of interest is 190 bp. Goat IgG was used as a negative control. bp, base pairs; MK,
marker.C, U87 cells were transfectedwith different amounts of DN-NRF-1 construct (n 3). Bars show themean S.E. of LUC activity in arbitrary units. ***, p
0.001 as compared with mock-transfected cells. D, upper panel, representative Western blot of homogenates of transfected cells probed with anti-FLAG
antibody showing the expression ofWT-NRF-1 or DN-NRF-1. DN-NRF-1 is a deletion ofWT-NRF-1 lacking the transcription activation domain (
250 bp). Lower
panel, representative Western blot of loading control with anti-tubulin (38) antibody. Left, molecular mass markers in kDa. E, left panel, HeLa cells were
transiently transfected with DN-NRF-1 or WT-NRF-1, respectively (n  3). Bars show the mean  S.E. of endogenous L-IDE mRNA levels normalized by
TATA-binding protein (TBP) content. Right panel, HeLa cells were transiently transfectedwith PGC-1 (n 3). Bars show themean S.E. of endogenous NRF-1
and L-IDE mRNA levels normalized by TATA-binding protein content. F, bars show the mean  S.E. of the percentage of IDE levels as compared with
mock-transfected cells (100%). The amount of IDEwas determinedby ELISA in isolatedmitochondrial (Mito.) and cytosolic fractions of NRF-1- (left panel) (n
4) and PGC-1 (right panel) (n 4)-transfectedHeLa cells, respectively, and normalized bymgof total protein. *, p 0.05WT-NRF-1 versusDN-NRF-1.G, HEKSw
cells were exposed to 30M PQQ, and the endogenous PGC-1, NRF-1, and L-IDE transcript levels were determined by RT-qPCR after 30min, 1 h, 2 h, and 4 h,
respectively (n 3).White, PGC-1; dashed, NRF-1; and black, L-IDE. Bars show the mean S.E. of the expression of the genes normalized by TATA-binding
protein content.*, p 0.05 as compared with mock-transfected cells at each time point;, PGC-1 versus L-IDE. Error bars represent S.E.
FIGURE 5. Themitochondrial biogenesis pathway is altered in AD brains.
mRNA from frozen hippocampal samples was isolated, and endogenous
PGC-1, NRF-1, and L-IDE transcript levels were determined by RT-qPCR. A
strong positive correlation was observed in controls (ND) (upper panels)
between PGC-1 or NRF-1 and L-IDE in contrast to AD (lower panels) in which
the correlation decreased.
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of A40 promotes mitochondrial dysfunction. In addition,
HEKSw cells treated with -secretase inhibitor (DAPT) dimin-
ishedmitA levels as compared with DMSO-treated cells (3.51
versus 5.16 pg/mg) and reverted the RCR impairment (1.73 
0.04 versus 2.09  0.04; p  0.05). These results are in agree-
ment with the mitochondrial enzyme dysfunctionality due to
A40 accumulation as reported (43). Interestingly, after PQQ
treatment, a significant increase in the RCR value (
29%) was
observed as comparedwithHEKSwuntreated cells (2.24 0.03
versus 1.73 0.04; p 0.05) in accordance with increments in
L-IDEmRNA levels (Fig. 4G) andmitochondrial content deter-
mined by flow cytometry (Fig. 7A). The impact of L-IDE on
RCRwas determined by treatment of HEKSw cells with control
siRNA or IDE siRNA. Our results showed an impairment of

25% after IDE siRNA treatment without changes in cell via-
bility (more that 90%). Taking into account that RCR is calcu-
lated as state 3u/state 4o, the return to control values observed
after PQQ treatment and the decrements observed after IDE
siRNA treatment, respectively, could be due to an enhance-
ment (13.9  1.18 versus 6  1.3.; p  0.05) or inhibition
(7.73 0.16 versus 9.3 1.08.;p 0.05) of state 3u as compared
with HEKSw cells, respectively (Fig. 7B). Our results suggest
that IDE-Met1 impactsmitA40 accumulation and mitochon-
drial functionality. Overall, we showed that the PGC-1/NRF-1
pathwaymodulatesmitA through the regulation of L-IDE and
that this pathway may be changed in AD brain.
DISCUSSION
NRF-1 acts as a central transcription factor that regulates
IDE transcription (22). By using DAVID, which allows in silico
analysis of regulatory sequences of 14,821 human genes, we
realized that 471 genes (3.17%) have the NRF-1 DNA-binding
motif in the proximal region (250/1), and nine of those are
mitochondrial genes, suggesting that at least part of hIDE tran-
scriptional regulation is similar to that of this specific subset of
genes. TheNRF-1 site is located in aCpG-rich island. In normal
cells, methylation occurs predominantly in CG-poor regions,
whereas theCpG island remains unmethylated. The exceptions
are the extensive methylation of CpG islands associated with
transcriptional inactivation of regulatory regions of genes.
Methylation of DNA is an important regulator of gene expres-
sion, and early studies of genomicDNAmethylation reported it
to decrease with age (44, 45). However, recent evidence indi-
cates that this relationship is more complex. A recent study
reported positive correlations betweenCpG islandmethylation
and aging (46). The change in the epigenetic signature with age
is likely to be significantly determined by environmental expo-
sures, including diet, tobacco smoke, alcohol, and previous ill-
nesses and therapies (47). The biological consequence of the
methylation status in the cluster of theNRF-1 binding site is not
clear. Although the reporter gene experiments underlined the
potential importance of promoter methylation in IDE expres-
sion, the assay determined the effects of methylation of the
whole promoter fragment rather than individual or clusters of
CpGs. However, one of the CpGs analyzed corresponds to the
polymorphism C/T at position 51 of the IDE promoter; this
haplotype with the G/T at position 1002 was described as a
protective (1002G/51T) or risk (1002T/51C) factor for
sporadic AD in the Chinese population (48). In this context,
FIGURE6.Mitochondrial IDEexpression impactsA catabolismandmito-
chondrial functionality. A, representative Western blot showing the purity
ofmitochondria (Mito.) isolated from cellular extracts (Cell. Ext.) (8g/lane) of
transfected HEKSw cells probed with anti-actin (38) (upper panel) and with
anti-TOM20 (Santa Cruz Biotechnology) (lower panel) antibodies, respec-
tively. Left, molecular mass markers in kDa. IDE (B) and A40 (C) levels were
determined by ELISA in mitochondria isolated from HEKSw cells transfected
with control siRNA (si-RNA-CNT) or siRNA specific for IDE (si-RNA-IDE). Bars
show themean S.E. ofmitochondrial IDE andA40 amounts normalizedby
mg of total protein. *, p 0.01, control siRNA versus IDE siRNA (n 3). Error
bars represent S.E.
FIGURE 7. L-IDE expression modulates the RCR in HEKSw cells. A, incre-
ment in cellular mitochondrial content after PQQ exposure detected after
10-N-nonyl acridine orange staining and flow cytometry assay. Representa-
tive histograms (cell counts at each fluorescence intensity, 101–102) for con-
trol (white) and PQQ (black) are shown. Significant differences were detected
in fluorescence values between control and PQQ-treated cells (mean values
in arbitraryunits 28.740.20 versus30.310.23;p0.001).B,mitochondrial
respiration was determined by oxygen electrode measurement in HEKSw
cells exposed or not to PQQ and treated with control siRNA (si-RNA-CNT) or
IDE siRNA. *, p 0.05, control (CNT) versus PQQ and control siRNA versus IDE
siRNA. Inset, mean S.E. of state 4, state 3, and RCR (n 5). Error bars repre-
sent S.E.
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methylation of C-51 may result in a down-regulation of IDE
transcription and a potential risk factor for AD.
We have described in AD brains a poor correlation between
the expression of genes involved in mitochondrial biogenesis
and L-IDE, supporting the concept that impairments in mito-
chondrial biogenesis due to repression of PCG-1-dependent
genes preclude mitA degradation and that this mechanism
may be an upstream event responsible for the mitochondrial
dysfunction, a prominent and early feature of AD brain (49)
mainly characterized by reduced energymetabolism (50), lower
expression of mitochondrial DNA (51), excessive mitochon-
drial fragmentation, and abnormal mitochondrial distribution
(52, 53).
The link described here among mitochondrial biogenesis,
IDE promoter activation, and L-IDE expression supports a con-
certed action of NRF-1 together with PPAR (co-activated by
PGC-1) (21) to enhance hIDE transcription. The role of
PCG-1 in gluconeogenesis and insulin resistance (54); the rel-
evance of the insulin-PI3K-akt pathway in PPAR (21), NRF-1
activity (55), and IDE expression (56); and the metabolic phe-
notype of insulin resistance described in AD and diabetes mel-
litus patients confirm the relevance of our results in under-
standing the role of hIDE in the pathogenesis of both human
diseases (Fig. 8). Indeed, the study of the transcriptional regu-
lation of hIDEbymutatedNRF-1 associatedwith the pathogen-
esis of type 2 diabetes mellitus (57, 58) may be of significance to
molecular mechanisms underlying the disease.
This study favors the notion that IDE has an “eclipsed” dis-
tribution (59) with huge amounts of the cytosolic isoform (IDE-
Met42) that maskmitochondrial IDE (IDE-Met1). The high lev-
els of cytosolic IDE may be explained by the multiplicity and
abundance of the “short” transcripts. Taking into account that
mitochondrial accumulation of A may not be a physiologic
process, the role of IDE-Met1may be to degrade freemitochon-
drial targeting peptides and other small peptide substrates that
may be toxic to organellar function. The identification that
IDE-Met1 isoform is expressed in human brain, that the PGC-
1/NRF-1 pathwaymodulatesmitA through the regulation of
L-IDE mRNA expression, and that this pathway has a func-
tional significance in mitochondrial function may provide a
starting point for examining novel prophylactic strategies in the
treatment of mitochondrial dysfunction in AD.
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